Christian Blank, Head of Melanoma and Sarcoma Division at European Institute of Oncology, shared a post on LinkedIn:
“Congrats Minke Lucas to your ground-breaking work showing for the first time that immune-signature based pre-selection of patients will potentially allow for dose-escalation of neoadjuvant immunotherapy, resulting in increased pathologic response without increasing the toxicity.
We need to analyse in 2026 more the concept of a patient’s immune activability.”
More posts featuring Christian Blank
